Results 101 to 110 of about 6,212,855 (344)

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. [PDF]

, 2018
BACKGROUND: Although coronary computed tomographic angiography (CTA) improves diagnostic certainty in the assessment of patients with stable chest pain, its effect on 5-year clinical outcomes is unknown.
Adamson, Philip D., Berry, Colin, Boon, Nicholas A., Boylan, Heather, Brown, Ammani, Connolly, Eugene, Dweck, Marc R., Farrell, Lesley, Flather, Marcus, Forbes, John, Frood, Alison, Glover, Caroline, Hunter, Amanda, Johnstone, Janet, Lanaghan, Kirsten, Lewis, Stephanie, MacLean, Scott, Mangion, Kenneth, McGlynn, Deborah, McGregor, Lorraine, McLennan, Evonne, Mills, Nicholas L., Mordi, Ify, Murdoch, Laura, Newby, David E., Norrie, John, Paterson, Victoria, Roditi, Giles, Shah, Anoop S.V., Steedman, Tracey, Teenan, Marion, Teyhan, Fiona, The SCOT-HEART Investigators,, Timmis, Adam D., Tzemos, Nikolaos, van Beek, Edwin J.R., Williams, Michelle C., Woodward, Rosie   +37 more
core   +6 more sources

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

Molecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Elin Borgen, Cecilie Bendigtsen Schirmer, Bjørnar Gilje, Øystein Garred, Jon Lømo, Marius Stensland, Oddmund Nordgård, Ragnhild Sørum Falk, Randi R. Mathiesen, Hege G. Russnes, Jon Amund Kyte, Bjørn Naume   +13 more
wiley   +1 more source

Competing risks analysis for neutrophil to lymphocyte ratio as a predictor of diabetic retinopathy incidence in the Scottish population

BMC Medicine, 2023
Background Diabetic retinopathy (DR) is a major sight-threatening microvascular complication in individuals with diabetes. Systemic inflammation combined with oxidative stress is thought to capture most of the complexities involved in the pathology of ...
Aravind Lathika Rajendrakumar, Simona M. Hapca, Anand Thakarakkattil Narayanan Nair, Yu Huang, Mehul Kumar Chourasia, Ryan Shun-Yuen Kwan, Charvi Nangia, Moneeza K. Siddiqui, Prathiba Vijayaraghavan, Shona Z. Matthew, Graham P. Leese, Viswanathan Mohan, Ewan R. Pearson, Alexander S. F. Doney, Colin N. A. Palmer   +14 more
doaj   +1 more source

Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting [PDF]

, 2007
Background: An elevated preoperative white blood cell count has been associated with a worse outcome after coronary artery bypass grafting (CABG). Leukocyte subtypes, and particularly the neutrophil-lymphocyte (N/L) ratio, may however, convey superior ...
Buchan, Keith G., Croal, Bernard L., Cuthbertson, Brian, El-Shafei, Hussein, Gibson, George, Gibson, Patrick H., Hillis, Graham S., Ifezulike, Ada I., Jeffrey, Robert R., Small, Gary R.   +9 more
core   +1 more source

Subtleties in the interpretation of hazard ratios

, 2018
The hazard ratio is one of the most commonly reported measures of treatment effect in randomised trials, yet the source of much misinterpretation. This point was made clear by (Hernan, 2010) in commentary, which emphasised that the hazard ratio contrasts populations of treated and untreated individuals who survived a given period of time, populations ...
Martinussen, Torben, Vansteelandt, Stijn, Andersen, Per Kragh   +2 more
openaire   +2 more sources

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure. [PDF]

, 2019
Background Blacks harbor more cardiovascular risk factors than whites, but experience less atrial fibrillation ( AF ). Conversely, whites may have a lower risk of heart failure ( CHF ).
Alonso, Alvaro, Arking, Dan, Chen, Lin, DeFilippi, Christopher, Dewland, Thomas, Gottdiener, John, Heckbert, Susan, Hoogeveen, Ron, Marcus, Gregory, Psaty, Bruce, Selvin, Elizabeth, Vittinghoff, Eric, Whitman, Isaac   +12 more
core  

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Survival analysis in clinical trials: Basics and must know areas

Perspectives in Clinical Research, 2011
Many clinical trials involve following patients for a long time. The primary event of interest in those studies is death, relapse, adverse drug reaction or development of a new disease.
Ritesh Singh, Keshab Mukhopadhyay
doaj   +1 more source